Home / Solutions / Biotech Asset Readiness
Proposed Engagement
A structured view of the scientific case behind your next development milestone.
A compelling asset story requires more than a promising mechanism. It requires a clear understanding of the supporting evidence, remaining uncertainties, and milestones that matter to the next audience or decision.
AionWell’s proposed asset-readiness engagements are designed to help teams organize these questions into a more coherent development narrative.
Key Questions
- What is the central therapeutic hypothesis?
- Which evidence supports the proposed differentiation?
- What has been shown in relevant biological models?
- Which translational assumptions remain unresolved?
- Which milestones could materially strengthen the asset’s evidence package?
- What should stakeholders understand before the next decision?
Illustrative Deliverables
- Scientific Positioning Review — A structured summary of the asset’s core scientific proposition.
- Evidence Readiness Map — A review of available evidence and key gaps.
- Development Risk Register — Critical uncertainties, dependencies, and assumptions.
- Milestone Prioritization — An organized view of potential next validation steps.
- Decision-Oriented Brief — A concise package supporting internal or external discussion.